Vaccination with a latch peptide provides serotypeindependent protection against group B streptococcus infection in mice

Shun Mei Lin, A. Yeung Jang, Yong Zhi, Shuang Gao, Sangyong Lim, Jae Hyang Lim, Joon Young Song, Paul M. Sullam, Joon Haeng Rhee, Ho Seong Seo

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Streptococcus agalactiae (group B streptococcus [GBS]) is a leading cause of invasive diseases in neonates and severe infections in elderly individuals. GBS serine-rich repeat glycoprotein 1 (Srr1) acts as a critical virulence factor by facilitating GBS invasion into the central nervous system through interaction with the fbrinogen Aa chain. This study revealed that srr1 is highly conserved, with 86.7% of GBS clinical isolates expressing the protein. Vaccination of mice with different Srr1 truncated peptides revealed that only Srr1 truncates containing the latch domain protected against GBS meningiThis. Furthermore, the latch peptide alone was immunogenic and elicited protective antibodies, which efciently enhanced antibody-mediated opsonophagocytic killing of GBS by HL60 cells and provided heterogeneous protection against 4 different GBS serogroups. Taken together, these fndings indicated that the latch domain of Srr1 may constitute an effective peptide vaccine candidate for GBS.

Original languageEnglish
Pages (from-to)93-102
Number of pages10
JournalJournal of Infectious Diseases
Volume217
Issue number1
DOIs
StatePublished - 1 Jan 2018

Bibliographical note

Publisher Copyright:
© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.

Keywords

  • Latch
  • Serine-rich repeat
  • Streptococcus agalactiae
  • Vaccine

Fingerprint

Dive into the research topics of 'Vaccination with a latch peptide provides serotypeindependent protection against group B streptococcus infection in mice'. Together they form a unique fingerprint.

Cite this